ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.
View Top Employees from ImmunoMet Therapeutics, Inc.Website | http://immunomet.com |
Revenue | $20 million |
Funding | $10.2 million |
Employees | 8 (8 on RocketReach) |
Founded | 2015 |
Address | 2450 Holcombe Blvd, Houston, Texas 77021, US |
Phone | (346) 772-0318 |
Technologies |
JavaScript,
HTML,
PHP
+8 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Business Services General, Biopharma, Business Services, Drug Discovery, Health Care, Science and Engineering, Pharmaceutical, Therapeutics |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies |
Looking for a particular ImmunoMet Therapeutics, Inc. employee's phone or email?
The ImmunoMet Therapeutics, Inc. annual revenue was $20 million in 2024.
Benjamin Cowen is the President, CEO and Co-founder of ImmunoMet Therapeutics, Inc..
8 people are employed at ImmunoMet Therapeutics, Inc..
ImmunoMet Therapeutics, Inc. is based in Houston, Texas.
The NAICS codes for ImmunoMet Therapeutics, Inc. are [541714, 54, 541, 54171, 5417].
The SIC codes for ImmunoMet Therapeutics, Inc. are [87, 873].